Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AVTXNASDAQ:DMACNASDAQ:GOSSNASDAQ:IVA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAVTXAvalo Therapeutics$4.79+3.2%$4.41$3.39▼$16.00$50.24M0.759,182 shs52,240 shsDMACDiaMedica Therapeutics$3.65+1.1%$3.96$2.14▼$6.82$154.81M1.2387,989 shs217,608 shsGOSSGossamer Bio$1.37-4.9%$1.12$0.66▼$1.55$327.32M1.851.44 million shs2.21 million shsIVAInventiva$3.34+1.5%$3.45$1.53▼$4.05$314.73M0.7564,346 shs8,756 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAVTXAvalo Therapeutics+3.23%+3.90%+27.73%-43.91%-63.27%DMACDiaMedica Therapeutics+1.11%+3.99%-10.10%-20.13%+68.98%GOSSGossamer Bio-4.86%+7.03%+14.17%+7.03%+110.77%IVAInventiva+1.49%-0.62%+6.85%+21.64%+25.06%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAVTXAvalo Therapeutics2.9284 of 5 stars3.55.00.00.00.01.71.3DMACDiaMedica Therapeutics1.325 of 5 stars3.51.00.00.02.50.00.0GOSSGossamer Bio3.6522 of 5 stars3.51.00.04.72.11.70.0IVAInventiva2.1088 of 5 stars3.42.00.00.00.01.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAVTXAvalo Therapeutics 3.00Buy$30.00526.30% UpsideDMACDiaMedica Therapeutics 3.00Buy$8.00119.18% UpsideGOSSGossamer Bio 3.00Buy$7.75465.69% UpsideIVAInventiva 2.80Moderate Buy$10.40211.47% UpsideCurrent Analyst Ratings BreakdownLatest AVTX, GOSS, DMAC, and IVA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/2/2025AVTXAvalo TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold ➝ Buy$15.005/29/2025DMACDiaMedica TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.005/16/2025GOSSGossamer BioThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$7.00 ➝ $8.005/16/2025GOSSGossamer BioWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$4.00 ➝ $4.004/17/2025GOSSGossamer BioThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$8.00 ➝ $7.004/4/2025IVAInventivaGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$12.00 ➝ $9.003/28/2025IVAInventivaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$13.00 ➝ $13.003/25/2025AVTXAvalo TherapeuticsJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageUnderperform ➝ Buy$23.003/25/2025AVTXAvalo TherapeuticsStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$36.00(Data available from 6/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAVTXAvalo Therapeutics$440K117.90N/AN/A$12.80 per share0.37DMACDiaMedica TherapeuticsN/AN/AN/AN/A$0.95 per shareN/AGOSSGossamer Bio$124.59M2.50N/AN/A$0.13 per share10.54IVAInventiva$9.20M34.73N/AN/A($1.21) per share-2.76Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAVTXAvalo Therapeutics-$35.13MN/A0.00N/AN/AN/A111.00%58.88%8/11/2025 (Estimated)DMACDiaMedica Therapeutics-$24.44M-$0.64N/AN/AN/AN/A-61.35%-55.53%8/6/2025 (Estimated)GOSSGossamer Bio-$56.53M-$0.23N/AN/AN/A-41.12%-128.98%-15.52%8/11/2025 (Estimated)IVAInventiva-$199.34MN/A0.00N/AN/AN/AN/AN/AN/ALatest AVTX, GOSS, DMAC, and IVA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025GOSSGossamer Bio-$0.18-$0.16+$0.02-$0.16$3.95 million$9.89 million5/13/2025Q1 2025DMACDiaMedica Therapeutics-$0.18-$0.18N/A-$0.18N/AN/A5/12/2025Q1 2025AVTXAvalo Therapeutics-$1.07-$1.25-$0.18-$1.25N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAVTXAvalo TherapeuticsN/AN/AN/AN/AN/ADMACDiaMedica TherapeuticsN/AN/AN/AN/AN/AGOSSGossamer BioN/AN/AN/AN/AN/AIVAInventivaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAVTXAvalo TherapeuticsN/A22.6122.61DMACDiaMedica TherapeuticsN/A8.028.02GOSSGossamer Bio6.705.715.71IVAInventivaN/A0.920.92Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAVTXAvalo Therapeutics87.06%DMACDiaMedica Therapeutics10.12%GOSSGossamer Bio81.23%IVAInventiva19.06%Insider OwnershipCompanyInsider OwnershipAVTXAvalo Therapeutics0.25%DMACDiaMedica Therapeutics7.30%GOSSGossamer Bio6.70%IVAInventiva32.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAVTXAvalo Therapeutics4010.83 million10.80 millionNot OptionableDMACDiaMedica Therapeutics2042.88 million39.75 millionOptionableGOSSGossamer Bio180227.30 million212.07 millionOptionableIVAInventiva10095.66 million65.05 millionNot OptionableAVTX, GOSS, DMAC, and IVA HeadlinesRecent News About These CompaniesInventiva appoints former Calliditas CEO to board of directorsJune 11, 2025 | uk.investing.comInventiva (NASDAQ:IVA) Stock Price Up 0.8% - Here's WhyJune 11, 2025 | marketbeat.comINVENTIVA: Inventiva Announces the Appointment of Renée Aguiar-Lucander to its Board of DirectorsJune 11, 2025 | finanznachrichten.deInventiva Announces the Appointment of Renée Aguiar-Lucander to its Board of DirectorsJune 10, 2025 | manilatimes.netInventiva S.A. (NASDAQ:IVA) Short Interest Down 12.1% in MayJune 4, 2025 | marketbeat.comInventiva (IVA) Upgraded to Buy: What Does It Mean for the Stock?June 3, 2025 | zacks.comINVENTIVA: Inventiva to Participate in the Upcoming Jefferies Global Healthcare Conference and UBS Spring Biotech ConferenceMay 27, 2025 | finanznachrichten.deInventiva to Participate in the Upcoming Jefferies Global Healthcare Conference and UBS Spring Biotech ConferenceMay 27, 2025 | globenewswire.comInventiva S.A. reports Q1 resultsMay 23, 2025 | seekingalpha.comINVENTIVA: Inventiva reports 2025 First Quarter Financial InformationMay 23, 2025 | finanznachrichten.deInventiva reports 2025 First Quarter Financial Information¹May 23, 2025 | globenewswire.comResults of the Votes of the Combined Shareholders' General Meeting of May 22, 2025May 23, 2025 | globenewswire.comDescription of the Share Repurchase Program Covered by the Liquidity Agreement with Kepler ChevreuxMay 22, 2025 | uk.finance.yahoo.comINVENTIVA: Inventiva secures the €116 million second tranche of its structured financing of up to €348 millionMay 6, 2025 | finanznachrichten.deInventiva Secures €115.6 Million Through T2 Subscription AgreementMay 5, 2025 | tipranks.comInventiva secures €116 million second tranche of structured financing of up to €348 millionMay 5, 2025 | msn.comInventiva secures the €116 million second tranche of its structured financing of up to €348 millionMay 5, 2025 | globenewswire.comCombined General Meeting of May 22, 2025 - Availability of the preparatory documentsApril 30, 2025 | globenewswire.comInventiva announces the publication in Clinical Gastroenterology and Hepatology of its analysis of new biomarker signatures predictive of histological response in patients with MASH treated with lanifibranorApril 24, 2025 | globenewswire.comINVENTIVA: Inventiva announces filing of its 2024 Universal Registration Document and 2024 Annual Report on Form 20-FApril 15, 2025 | finanznachrichten.deInventiva announces filing of its 2024 Universal Registration Document and 2024 Annual Report on Form 20-FApril 15, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeAVTX, GOSS, DMAC, and IVA Company DescriptionsAvalo Therapeutics NASDAQ:AVTX$4.79 +0.15 (+3.23%) Closing price 06/23/2025 04:00 PM EasternExtended Trading$4.76 -0.03 (-0.52%) As of 05:51 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Avalo Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders. It also develops Quisovalimab (AVTX-002), an Anti-LIGHT mAb which is in phase II for immune-inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland.DiaMedica Therapeutics NASDAQ:DMAC$3.65 +0.04 (+1.11%) Closing price 06/23/2025 04:00 PM EasternExtended Trading$3.66 +0.00 (+0.14%) As of 06/23/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease. The company also develops DM300, which is in preclinical stage for the treatment of severe inflammatory diseases. In addition, it develops treatment for neurological disease. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.Gossamer Bio NASDAQ:GOSS$1.37 -0.07 (-4.86%) Closing price 06/23/2025 04:00 PM EasternExtended Trading$1.36 -0.01 (-0.44%) As of 04:22 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.Inventiva NASDAQ:IVA$3.34 +0.05 (+1.49%) As of 06/23/2025 03:53 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company was founded in 2011 and is headquartered in Daix, France. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Microsoft Stock Holds Steady as AI Drives Workforce Shift Top International ETFs With Dividends and Market-Beating Returns D-Wave Goes International With South Korea Partnership BigBear.ai Poised to Benefit as Palantir Dominates AI Defense Kroger Stock Confirms Buy Signal as Uptrend Gains Strength Darden Stock Set to Sizzle After Blowout Q4 and $1B Buyback Alphabet’s Comeback: The Hidden Engines Powering Google New All-Time Highs Coming for Broadcom? Wall Street Says Yes Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
